Transgenic mice expressing a dominant-negative CREB transcription factor in the heart developed progressive dilated cardiomyopathy with over 40% mortality by 20 weeks compared to 0% in controls.
This study establishes a transgenic mouse model of dilated cardiomyopathy by expressing a dominant-negative CREB transcription factor, implicating CREB as an important regulator of cardiac myocyte function.
Absolute Event Rate: 40% vs 0%
p-value: p=<0.000005
Idiopathic-dilated cardiomyopathy (IDC) is a common primary myocardial disease of unknown etiology characterized by progressive biventricular failure, cardiac dilatation, and premature mortality. Here we show that transgenic mice expressing a dominant-negative form of the CREB transcription factor (CREBA133) under the control of the cardiac myocyte-specific alpha-MHC promoter develop dilated cardiomyopathy that closely resembles many of the anatomical, physiological, and clinical features of human IDC. Between 2 and 20 wk of age, these mice develop four chamber cardiac dilatation, decreased systolic and diastolic left ventricular function, and attenuated contractile responses to the beta-adrenergic agonist, isoproterenol. Histologically, the CREBA133 hearts demonstrated both atrophic and hypertrophied fibers as well as significant interstitial fibrosis. These anatomical and hemodynamic changes were associated with hepatic congestion and peripheral edema, intracardiac thrombi, and premature mortality. Taken together, these results implicate CREB as an important regulator of cardiac myocyte function and provide a genetic model of dilated cardiomyopathy which should facilitate studies of both the pathogenesis and therapy of this clinically important disorder.
Fentzke等(Mon,)在扩张型心肌病中进行了一项研究(n=144)。评估了在20周时具有显性负性CREB(CREBA133)转基因表达的心脏与非转基因控制同胞的死亡率(p=<0.000005)。表达显性负性CREB转录因子的转基因小鼠相比于对照组在20周时出现了超过40%的逐渐扩张型心肌病死亡率,而对照组为0%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: